• Partial BACE1 Inhibition Reduces Amyloid Beta Without Synapt

  2026-04-29

  Satir et al. (2020) demonstrate that partial inhibition of BACE1, leading to less than 50% reduction in amyloid beta production, spares synaptic transmission in cultured neurons. This finding informs Alzheimer's disease research by indicating a therapeutic window for BACE inhibitor use that may avoid synaptic side effects.

• Safe DNA Gel Stain: Protocols and Best Practices for DNA/RNA

  2026-04-29

  Safe DNA Gel Stain (SKU A8743) offers a less mutagenic, high-sensitivity alternative to ethidium bromide for DNA and RNA visualization in agarose or acrylamide gels. It is best suited for researchers prioritizing safety and cloning efficiency, though it is less effective for low molecular weight DNA bands (100–200 bp) and not intended for diagnostic use.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-04-28

  This article reviews recent evidence demonstrating that the transcriptional co-regulator complex LMO2/LDB1 promotes acute myeloid leukemia (AML) development by supporting leukemic cell proliferation and survival. The study’s mechanistic dissection of LMO2/LDB1 interactions provides actionable targets for future leukemia research and therapeutic strategies.

• Chronic E-64 Cathepsin Inhibition in Salt-Sensitive Hyperten

  2026-04-28

  This study rigorously investigated the effects of chronic E-64 administration, an irreversible L-trans-epoxysuccinyl peptide cysteine protease inhibitor, in a rat model of salt-sensitive hypertension. The key finding is that sustained cathepsin inhibition by E-64 did not impact blood pressure progression or kidney injury, highlighting the complexity of cysteine cathepsin roles in cardiovascular-renal disease.

• H3K18 Lactylation Drives NOD2-Linked Pyroptosis in Astrocyte

  2026-04-27

  Li et al. (2025) reveal that H3K18 lactylation enhances NOD2 expression, promoting pyroptotic cell death in astrocytes exposed to bilirubin. This study uncovers a glycolysis-epigenetic-inflammation axis central to neuroinflammation, offering new mechanistic insight and potential therapeutic targets for bilirubin encephalopathy.

• TSPAN18 Protects STIM1 to Promote Bone Metastasis in Prostat

  2026-04-27

  Zhou et al. (2023) reveal that TSPAN18 enhances bone metastasis in prostate cancer by shielding STIM1 from TRIM32-mediated ubiquitination, thereby stabilizing STIM1 and augmenting Ca2+ signaling. These findings establish the TSPAN18-STIM1 axis as a promising target for therapeutic intervention in metastatic prostate cancer.

• LACTB Mediates Mitochondrial Remodeling for Apoptosis Contro

  2026-04-26

  Recent research identifies LACTB as a pivotal regulator of inner mitochondrial membrane (IMM) remodeling during apoptosis, acting independently of canonical outer membrane pathways. This mechanistic insight enhances our understanding of mitochondrial dynamics in tumor suppression and provides new avenues for targeted apoptosis research.

• Dehydroepiandrosterone (DHEA): Applied Protocols for Neuropr

  2026-04-25

  Dehydroepiandrosterone (DHEA) stands as a pivotal neuroprotection agent with validated utility in both neural and ovarian models. This article translates the latest mechanistic insights and protocol refinements into practical guidance for researchers, emphasizing troubleshooting strategies and the unique advantages of sourcing from APExBIO.

• In Vitro Metrics for Anti-Cancer Drug Response: Insights and

  2026-04-24

  Schwartz's dissertation critically reevaluates how in vitro anti-cancer drug responses are measured, separating the concepts of proliferative arrest and cell death using dual-metric analysis. The study highlights significant differences in how drugs like artemisinin derivatives affect cancer cells, providing researchers with a more precise framework for interpreting drug efficacy and optimizing experimental design.

• JSH-23: NF-κB Inhibitor Workflow Innovations in Inflammation

  2026-04-24

  JSH-23 enables precise, reproducible inhibition of NF-κB signaling for advanced inflammation research, standing out with its clean mechanism and robust performance in vitro and in vivo models. This guide illustrates optimized experimental workflows, troubleshooting, and strategic comparisons, empowering researchers to unlock deeper insights using APExBIO’s JSH-23.

• Z-LEHD-FMK: Irreversible Caspase-9 Inhibitor for Optimized A

  2026-04-23

  Z-LEHD-FMK empowers researchers to dissect mitochondria-mediated apoptosis with unmatched selectivity, improving both cancer and neuroprotection studies. Leveraging recent mechanistic insights and rigorously defined workflows, this APExBIO tool unlocks new precision in apoptosis assays and translational models.

• Elobixibat Hydrate: Applied Protocols for IBAT Inhibitor Res

  2026-04-23

  Elobixibat hydrate, a highly selective ileal bile acid transporter inhibitor, enables robust translational research in gastrointestinal and metabolic disorders. This guide details practical workflows, advanced use-cases, and troubleshooting strategies that maximize reproducibility and data quality for studies on constipation, colonoscopy preparation, and metabolic modulation.

• Cy5 NHS ester(Et): Technical Workflow Guide for Protein Labe

  2026-04-22

  Cy5 NHS ester(Et) enables precise fluorescent labeling of biomolecules by targeting primary amines, making it suitable for protein fluorescent labeling, immunofluorescence staining, and flow cytometry fluorescent probe development. It is not recommended for applications requiring ethanol solubility or long-term storage of prepared solutions, and should be used promptly after dissolution for optimal results.

• Phosphatase Inhibitor Cocktail 1: Empowering Phosphoproteomi

  2026-04-22

  APExBIO’s Phosphatase Inhibitor Cocktail 1 (100X in DMSO) stands apart as a robust alkaline phosphatase inhibitor, enabling accurate protein phosphorylation preservation during complex tissue and cell-based workflows. This article reveals optimized protocols, troubleshooting strategies, and real-world scenarios that harness the cocktail’s broad-spectrum efficacy for reproducible phosphoproteomic analysis.

• Ertugliflozin (PF-04971729): Selective SGLT2 Inhibitor Evide

  2026-04-21

  Ertugliflozin (PF-04971729) is a highly selective SGLT2 inhibitor with over 2000-fold selectivity, providing robust glucose reabsorption inhibition and cardiovascular benefits in type 2 diabetes research. Recent systematic reviews affirm its efficacy in reducing heart failure hospitalizations, while APExBIO supplies validated, high-purity PF-04971729 for translational and bench studies.

453 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page